IPH6501 in Relapsed and/or Refractory Non-Hodgkin Lymphoma

What is the Purpose of this Study?

The purpose of this study is to determine the safety and tolerability of an experimental drug called IPH6501, as well as evaluate its activity against cancerous cells causing lymphoma. The study focuses on people who have been diagnosed with advanced relapsed and/or refractory non-Hodgkin’s lymphomas (lymphoma that has come back or is resistant to treatment), specifically diffuse large B cell lymphoma, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, or marginal zone lymphoma. Study procedures include vital signs collection, physical exams, blood and urine samples collection, electrocardiograms, computer tomography scans, biopsies, and administration of the study drug. IPH6501 is a molecule manufactured in a laboratory to use the patient’s own immune system (natural defenses) for acting against cancer cells through different mechanisms that might slow down and/or destroy cancer cell growth.


Eligibility

  • * Patients with advanced histologically confirmed, documented CD20+ B-cell non-Hodgkin's lymphoma (NHL) including the following types defined by WHO 2016: Diffuse Large B Cell Lymphoma (DLBCL); high grade; thymic; Follicular Lymphoma (FL); Mantle cell lymphoma (MCL); Marginal zone lymphoma (MZL)
  • * Relapsed, progressive and/or refractory disease without established alternative therapy
  • * Must have received at least 2 prior systemic therapies including at a minimum anti-CD20 antibody therapy (e.g., rituximab) potentially in combination with chemotherapy and/or relapsed after autologous stem cell rescue.
  • * Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2
Show more

Where can I participate?

CS Cancer at Cedars-Sinai Medical Center : Emilie Douine-Barthelemy

More about this Clinical Trial

What is the full name of this clinical trial?

IPH6501-101: A Phase 1/2, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of IPH6501 in Patients with Relapsed and/or Refractory CD20-expressing Non-Hodgkin Lymphoma

Study Details
Disease Type/Condition

Non-Hodgkin's Lymphoma

Principal Investigator

Merchant, Akil

Co-Investigators

David Oveisi, Hannah Lee, Joshua Sasine, Justin Darrah, Noah Merin, Robert Vescio, Ronald Paquette

Age Group

Adult

Phase

I/II

IRB Number

STUDY00003173

ClinicalTrials.gov ID

NCT06088654

Key Eligibility
ClinicalTrials.gov

How do I learn more about this study?
Name

Emilie Douine-Barthelemy

Email
emilie.douine-barthelemy@cshs.org
Study Detail
Disease Type/Condition

Non-Hodgkin's Lymphoma

Principal Investigator

Merchant, Akil

Age Group

Adult

Phase

I/II

IRB Number

IPH6501-101

ClinicalTrials.gov ID

NCT06088654

Key Eligibility
ClinicalTrials.gov

Contact
Name

Emilie Douine-Barthelemy

Email
emilie.douine-barthelemy@cshs.org